(NASDAQ: INMB) Inmune Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.27%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.72%.
Inmune Bio's earnings in 2026 is -$41,601,000.On average, 6 Wall Street analysts forecast INMB's earnings for 2026 to be -$20,428,112, with the lowest INMB earnings forecast at -$26,053,553, and the highest INMB earnings forecast at -$12,282,389. On average, 5 Wall Street analysts forecast INMB's earnings for 2027 to be -$23,320,588, with the lowest INMB earnings forecast at -$31,785,334, and the highest INMB earnings forecast at -$13,957,260.
In 2028, INMB is forecast to generate -$13,558,482 in earnings, with the lowest earnings forecast at -$17,455,880 and the highest earnings forecast at -$9,211,792.